The global chimeric antigen receptor (CAR)-T cell therapy market size was valued at USD 2.72 billion in 2024 and is expected to reach USD 6.65 billion by 2032, at a CAGR of 11.80% during the forecast period
The market growth is largely fueled by the increasing prevalence of cancer worldwide and the breakthrough clinical outcomes offered by CAR-T cell therapies, which have revolutionized treatment paradigms for hematologic malignancies and are expanding into solid tumor indications
Furthermore, growing investment in advanced cell-based immunotherapies, regulatory support, and the rapid pace of biotechnological innovation are establishing CAR-T cell therapy as a cornerstone of next-generation cancer treatment. These converging factors are accelerating the adoption of CAR-T solutions, thereby significantly boosting the industry’s growth